Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.23.3
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Basic and diluted numerator:    
Net loss attributable to iBio, Inc. $ (29,311) $ (29,512)
Preferred stock dividends - iBio CMO Preferred Tracking Stock   (88)
Net loss available to iBio, Inc. stockholders (29,311) (29,600)
Loss from discontinued operations (35,699) (20,791)
Net loss available to iBio, Inc. stockholders $ (65,010) $ (50,391)
Basic and diluted denominator:    
Weighted-average common shares outstanding - basic 12,245 8,721
Weighted-average common shares outstanding - diluted 12,245 8,721
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (2.39) $ (3.39)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (2.39) (3.39)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (2.92) (2.39)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (2.92) (2.39)
Per share amount basic (5.31) (5.78)
Per share amount diluted $ (5.31) $ (5.78)